Loading clinical trials...

UNKNOWN

Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.

NCT00759382•European Lung Cancer Working Party

Summary

The primary aim of this non interventional study is to assess the independent prognostic role on overall survival of primary tumour 18F-FDG uptake value (SUVmax) measured on 18fluorodeoxyglucose positron emission tomography (18F-FDG-PET) in patients with non-metastatic non-small cell lung cancers treated with curative intent, taking into account the other conventional prognostic factors (performance status, age, sex, disease stage).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Pathologically demonstrated NSCLC
•Stage I-III treated by curative treatment by surgery with or without chemotherapy (induction or adjuvant) or by chemoradiotherapy
•Inoperable patients treated by exclusive radiotherapy
•A whole-body (skull base to mid thighs) FDG-PET or a combined FDG-PET/CT on a dedicated machine, performed before any anticancer treatment
•FDG-PET or combined FDG-PET/CT has to be previously standardised according to the procedure described in appendix IV
•Written informed consent
•Accessibility to follow-up
•Age \> 18 years

Exclusion Criteria

•Prior anticancer treatment (surgery, radiotherapy or chemotherapy)
•Stage IV NSCLC
•A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix and cured malignant tumour (more than 5-year disease free interval)
•Uncontrolled diabetes mellitus (fast glycaemia above 130 mg/dl)
•Pregnancy and lactating woman
•Unavailability to send a copy of the PET or PET-CT (DICOM format) to the data centre

Locations (6)

Department of Pneumology RHMS Hôpital de la Madeleine

Ath, Belgium

Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet

Brussels, Belgium

Department of Pneumology CHU Charleroi

Charleroi, Belgium

Department of Pneumology Hôpital Saint-Joseph

Gilly, Belgium

Hôpital Ambroise Paré

Mons, Belgium

Department of Pneumology Centre Hospitalier de Mouscron

Mouscron, Belgium

Key Dates

Start Date

July 1, 2008

Primary Completion Date

January 1, 2021

Completion Date

January 1, 2022

Last Updated

August 23, 2021

Enrollment

340

ESTIMATED participants

Conditions

Non Small Cell Lung Carcinoma

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

NCT00592007

Non Small Cell Lung Carcinoma

View study

COMPLETEDPHASE1

Phase I Study of Vorinostat and Sorafenib in Advanced Cancer

NCT00635791

Malignant Solid TumourRenal Cell Carcinoma+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 23, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.

Inclusion Criteria

Exclusion Criteria

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

Phase I Study of Vorinostat and Sorafenib in Advanced Cancer

Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC